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ABSTRACT 
It is well known that many genes implicated in the development and progression of breast 
cancer undergo aberrant alternative splicing events to produce proteins with pro-cancer 
properties. These changes in alternative splicing can arise from mutations or single nucleotide 
polymorphisms (SNPs) within the DNA sequences of cancer-related genes which can 
strongly affect the activity of splicing factors and influencing the splice site choice. However, 
it is important to note that absence of mutations is not sufficient to prevent misleading 
choices in splice site selection.  There is now increasing evidence to demonstrate that the 
expression profile of ten splicing factors (including SRs and hnRNPs) and eight RNA-
binding proteins changes in breast cancer cells compared to normal cells. These 
modifications strongly influence the alternative splicing pattern of many cancer-related genes 
despite the absence of any detrimental mutations within their DNA sequences. Thus, a 
comprehensive assessment of the splicing factors status in breast cancer is important to 
provide insights into the mechanisms that lead to breast cancer development and metastasis. 
Whilst most studies focus on mutations that affect alternative splicing in cancer-related 
genes, this review focuses on splicing factors and RNA-binding proteins that are themselves 
deregulated in breast cancer and implicated in cancer-related alternative splicing events. 
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INTRODUCTION 
The majority of human protein-coding genes produce multiple mRNA transcripts by 
alternative splicing. This RNA processing event is mediated by a complex interplay of 
splicing factors (SFs) and defined RNA sequences (splice sites) within pre-mRNA 
transcripts. Splice sites are short conserved sequences located within the pre-mRNA that 
define the start/end of the exons and introns (Srebrow and Kornblihtt, 2006) (Table1,  
Figure1). Splice sites act as binding sites for the spliceosome - a multi component complex 
comprising of five small nuclear ribonucleoproteins (snRNPs) working with 100-200 
different non-snRNPs (McManus and Graveley, 2011). Selection of different splice sites is 
under the control of the splicing factors to either promote or prevent the recruitment of the 
spliceosome to the splice sites (Cartegni et al., 2002) (Figure 1).  
 
It is now established that aberrant alternative splicing events are associated with the onset and 
aggression of breast cancer (Dutertre et al., 2010). One such example is that of the BRCA1 
gene. BRCA1 is a tumour suppressor and mutations within its genetic sequence are associated 
with breast cancer (Orban and Olah, 2003). Alternative splicing of BRCA1 can generate 
variants which lack functional domains of the protein, thus compromising its tumour 
suppressor activity (Orban and Olah, 2003). The use of splicing assays reveals that mutations 
within specific sequences can affect the binding of splicing factors and this in turn strongly 
influences the splicing pattern of BRCA1 (Raponi et al., 2014). It is not uncommon that point 
mutations that affect the binding of splicing factors to the pre-mRNA can lead to erroneous 
control over the spliceosome, resulting in inaccurate alternative splicing of cancer-related 
genes (Cartegni et al., 2002). As such, the production of proto-oncogene splice variants might 
be favoured over tumour suppressor splice variants. In addition to mutations at binding sites, 
changes in the nuclear concentration of splicing factors can also have repercussions on splice 
site selection.  
 
Deregulation of splicing factors, and also other RNA-binding proteins, disrupts alternative 
splicing patterns of many genes associated with cancer (Grosso et al., 2008). This review 
focuses on splicing factors that have critical roles in regulating cancer-related genes 
associated with development and progression of breast cancer. 
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SPLICING FACTORS 
Splicing factors are RNA-binding proteins that interact with specific RNA sequences, or 
motifs, known as exonic splicing enhancers or silencers (ESEs, ISEs) and intronic splicing 
enhancer and silencers (ISEs, ISSs) (Figure 1) (Cartegni et al., 2002). Once the splicing 
factors are bound to the pre-mRNA, they can either guide or block the interaction between 
spliceosome and pre-mRNA (McManus and Graveley, 2011). Some splicing factors are 
capable of playing a dual role either activating or inhibiting splicing depending on the 
sequence that they bind. To date over 30 splicing factors have been well described in human 
cells and tissues (Venables et al., 2008; Twyffels et al., 2011) and they include two families: 
serine-arginine proteins (SR) and heterogeneous ribonucleoproteins (hnRNP). SRs usually 
favour the definition of exons and introns by binding enhancer sequences (Figure 1) and 
recruiting the spliceosome to the pre-mRNA, thus promoting splicing (Cartegni et al., 2002; 
David and Manley, 2010). Conversely, hnRNPs usually inhibit the splicing process by 
binding to silencer sequences (David and Manley, 2010) and blocking the interaction 
between pre-mRNA and the spliceosome or antagonizing the effects of the SRs (Cartegni et 
al., 2002). 
 
SR PROTEINS AND THEIR ROLE IN BREAST CANCER 
The SR proteins are a family of RNA-binding proteins that contain a serine/arginine rich (RS) 
domain at the carboxy-terminal region. At the amino-terminal region they have one or more 
RNA-recognition motifs (RRMs), required for binding to RNA (Manley and Tacke, 1996; 
Twyffels et al., 2011). Many SR proteins are involved in other processes of gene regulation 
including RNA maturation, decay, transport and translation. SR proteins can be recruited 
onto the nascent transcript by RNA Polymerase II together with members of the spliceosome 
(Fu, 1995; Twyffels et al., 2011). To date, twelve SR proteins have been well described 
(Twyffels et al., 2011) and six of them (SRSF1,2,3,5,6 and 10) are overexpressed in breast 
cancer (Huang et al., 2007; Dutertre et al., 2010); these proteins regulate RNA processing 
events of numerous genes involved in cell cycle regulation, cell proliferation, apoptosis, 
epithelial-to-mesenchymal transition (EMT), angiogenesis and also drug resistance (He et al., 
2004; Ghigna et al., 2005; Karni et al., 2007; Amin et al., 2011). 
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SRSF1 (SF2/ASF)  
SRSF1, the most well characterised SR protein, is involved in splicing, nonsense mediated 
decay, RNA translation, nuclear export of the mature RNA and also genome stability (Zuo 
and Manley, 1993; Li and Manley, 2005).  As a splicing regulator SRSF1 can interact with 
the polypyrimidine tract helping recruitment of snRNP U2 in proximity of the 3` splice site; 
SRSF1 also enables the selection of authentic 5` splice sites at the expense of cryptic splice 
sites (Krainer et al., 1990). SRSF1 has also been classified as proto-oncogene; it activates the 
Ras-Raf-MEK-ERK signalling pathway, commonly up-regulated in cancer, and its 
overexpression stimulates cell proliferation as well as inhibiting apoptosis (Karni et al., 2007; 
Anczukow et al., 2012; Das et al., 2012; Shimoni-Sebag et al., 2013). In breast cancer it is 
common to observe amplification of the SRSF1 gene and increased levels of its protein 
providing further evidence to highlight its importance in cancer-associated alternative 
splicing events. High levels of SRSF1 strongly affect alternative splicing of many genes 
linked with cancer pathophysiology including the ribosomal-protein kinase S6K1, the tumour 
suppressor BIN1 and kinases RON and MNK2 (Karni et al., 2007; Anczukow et al., 2012).  
 
The S6K1 gene (RPS6KB1) is frequently amplified in breast cancer resulting in a poor 
prognosis for the patient (Yamnik et al., 2009). S6K1 is a serine/threonine kinase and an 
important modulator of protein translation, cell growth and proliferation (Yamnik et al., 
2009) (Ben-Hur et al., 2013). With relevance to breast cancer, S6K1 phosphorylates estrogen 
receptor α (ERα), thus regulating its transcriptional activity (Yamnik et al., 2009). Alternative 
splicing of RPS6KB1 can produce a long splice variant (Iso-1) and a short splice variant (Iso-
2). Iso-2, but not Iso-1, enhances cell motility and transformation (Ben-Hur et al., 2013). 
SRSF1 strongly favours the production of Iso-2 by promoting inclusion of three alternative 
cassette exons of RPS6KB1: these are excluded in Iso-1 (Karni et al., 2007; Ben-Hur et al., 
2013). As a result, generation of the Iso-2 variant, which contains an alternative C-terminal 
region and which has oncogenic activity, prevails over the tumour suppressor Iso-1. 
 
The tumour suppressor BIN1 is another target of SRSF1. Overexpression of SRSF1 strongly 
promotes inclusion of exon 12A of BIN1 resulting in loss of its tumour suppressor activity 
(Karni et al., 2007). The tumour suppressor role of Bin1 resides in its ability to inhibit the 
activity of the oncogene Myc which regulates cell cycle and proliferation. Interestingly, a 
lack of Bin1 has often been seen in malignant breast cancer where it leads to a hyper-
activation of Myc and a poor prognosis of the disease (Ge et al., 1999; Ge et al., 2000).  
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SRSF1 also regulates alternative splicing of the proto-oncogene RON by promoting the 
production of a splice variant with even higher oncogenic properties compared to the wild 
type (Ghigna et al., 2005). RON gene is commonly overexpressed in cancer, including breast, 
leading to cell growth and invasion (Cunha et al., 2014). Wild type protein Ron is a tyrosine 
kinase receptor which plays a crucial role in epithelial to mesenchymal transition (EMT). 
During EMT, tumour cells acquire migratory and invasive properties which lead to a 
metastatic phase in different tumour tissues included breast (De Craene and Berx, 2013). 
Alternative splicing of the RON gene can generate a splice variant known as ∆Ron, which 
arises from exclusion of exon 11 (Ghigna et al., 2005). Such an event can be triggered by 
SRSF1 via binding to an exonic splicing enhancer (ESE) located within exon 12 of RON, and 
enhanced skipping of exon 11. Compared to the wild type, the ∆Ron splice variant lacks a 
portion of the extracellular domain; this bestows an extension of its half life and, as such, 
increases its potential oncogenic activity (Ghigna et al., 2005; Ghigna et al., 2008; Cunha et 
al., 2014). Moreover, ∆Ron is constitutively activated and can overcome proteolytic cleavage 
resulting in a more aggressive proto-oncogenic variant (Ghigna et al., 2005).  
 
Mitogen-activated protein (MAP) kinase-interacting kinases are a family of protein kinases 
which include splice variants Mnk2a and Mnk2b. Mnk2b is principally found in the nucleus 
and increases phosphorylation of the translational factor eIF4E (Scheper et al., 2003). 
Increased levels of Mnk2b result in hyper-activation of eIF4E which, in turn, is positively 
related to cell growth and survival of breast cancer cells (Li et al., 1997; Soni et al., 2008). 
Overexpression of SRSF1 regulates the inclusion of an exclusive exon 13b of the MKNK2 
gene promoting production of the Mnk2b splice variant (Karni et al., 2007). 
 
The oncogenic transcription factor c-Myb is highly expressed in breast tumours classified as 
ER positive and is required for the proliferative, anti-apoptotic and invasive properties of 
tumour cells (Drabsch et al., 2010; Thorner et al., 2010; Quintana et al., 2011; Knopfova et 
al., 2012). In contrast, other studies claim that a deficiency of c-Myb increases tumorigenesis, 
suggesting that it may also have tumour suppressor activity (Thorner et al., 2010). Two 
alternative splice variants of c-Myb have been described (Kumar et al., 2003). The most 
common splice variant, with anti-oncogenic activity, is a 75kDa protein; the second 89kDa 
splice variant of c-Myb, with pro-oncogenic properties, results from inclusion of an 
alternative exon 9A (Kumar et al., 2003). SRSF1 is able to regulate alternative splicing of c-
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Myb, although the precise mechanism of action remains unclear (Karni et al., 2007).  
Moreover, using qPCR it was revealed that several alternative splice variants of c-Myb 
mRNA exist from the inclusion of alternate exons: 8A, 9A, 9B, 10A, 13A, and 14A, although 
their precise roles, if any, have not as yet been described (O'Rourke and Ness, 2008).  SRSF1 
also regulates alternative splicing of apoptosis regulator Bcl-2 related genes. Bcl-2 family 
members include both pro-apoptotic and anti-apoptotic proteins. BIM and Mcl-1 are both two 
members of Bcl-2 family. In breast cancer cell lines, high expression of SRSF1 enhances 
inclusion of exon 2 of Mcl-1, promoting generation of anti-apoptotic variant of Mcl-1 
(Gautrey and Tyson-Capper, 2012). SRSF1 are also promotes production of two new splice 
variants of BIM (BIM γ1 and γ2) which fail to block the activity of the anti-apoptotic Bcl-2 
members (Anczukow et al., 2012).  
 
Vascular Endothelial Growth Factor (VEGF) is a protein that strongly promotes angiogenesis 
and its expression profile correlates with the estrogen receptor status of breast cancer cells 
(Adams et al., 2000). The VEGF gene undergoes alternative splicing to produce two splice 
variant groups that are either angiogenic or anti-angiogenic; exon 8 of VEGF includes two 3` 
splice sites termed proximal 3` splice site and distal 3` splice site. From selection of the 
proximal 3` splice site, angiogenic splice variants, such as VEGF165, can be generated. 
Conversely, from the selection of the distal 3` splice site, anti-angiogenic splice variants, such 
as VEGF165b, are produced (Amin et al., 2011). Interestingly, hyperphosphorylation of 
SRSF1 leads to an overproduction of the angiogenic variant VEGF165 by promoting 
selection of the proximal 3`splice site of the exon 8 (Amin et al., 2011).  
 
Another SRSF1 target is APC (Adenomatous polyposis coli); APC is a tumour suppressor 
that inhibits cell proliferation by blocking the transition to S phase of the cell cycle (Ho et al., 
1999). SRSF1 promotes inclusion of exon 14 of the APC gene resulting in a transcript with a 
premature stop codon; this leads to a deficiency of the mature tumour suppressor APC 
(Goncalves et al., 2009).   
 
The cyclin D1 gene (CCND1) is often overexpressed in different tumours included the breast 
(Roy and Thompson, 2006; Kim et al., 2009). The resulting protein, cyclin D, is involved in 
cell cycle progression stimulating the transition from cell phase G to phase S by associating 
with cyclin-dependent kinase proteins and tumor suppressors (Roy and Thompson, 2006; 
David and Manley, 2010). The most common splice variant of CCND1, called cyclin D1a, 
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includes all 5 exons of the gene, whereas cyclin D1b arises from inclusion of intron 4 and 
skipping of exon 5 (Olshavsky et al., 2010) resulting in a protein lacking a nuclear export 
signal and retention of nuclear cyclin D1b  (Kim et al., 2009; Paronetto et al., 2010). SRSF1 
modulates formation of proto-oncogenic cyclin D1b (Olshavsky et al., 2010) and 
upregulation of cyclin D1b occurs in different cancers, included breast (Kim et al., 2009; 
David and Manley, 2010; Paronetto et al., 2010). 
 
Rac1 is a GTPase that belongs to the Rho family and is mainly known for its role in cellular 
cytoskeleton growth and organization. Recent studies show that its activity also influences 
cell proliferation and its abundance is higher in breast tumour samples compared to normal 
tissue (Schnelzer et al., 2000; David and Manley, 2010). During alternative splicing of the 
Rac1 gene, SRSF1 promotes inclusion of exon 3b, resulting in a splice variant called Rac1b 
(David and Manley, 2010). Compared to Rac1, Rac1b is principally found in an activate state 
and it is positively associated to transcription of cyclin D and cell transformation (Zhou et al., 
2013).   
 
Whilst overexpression of SRSF1 is associated with breast cancer, its deficiency alters 
alternative splicing of the major hereditary breast cancer marker, BRCA1. To date many 
splice variants of BRCA1 have been documented (Lixia et al., 2007; Tammaro et al., 2012); 
variants lacking either exon 9 or 10 are amongst the most commonly investigated in breast 
cancer (Orban and Olah, 2003) (Tammaro et al., 2012). Knockdown of SRSF1 has shown to 
promote exclusion of both exons 9 and 10 of BRCA1 (Karni et al., 2007) altering the function 
of this important tumour suppressor. Amongst its many roles, BRCA1 is involved in DNA 
damage repair, chromatin remodelling and cell cycle control. It contains several domains for 
interacting with transcriptional factors, such as the tumour suppressor p53, and also with 
BRCA1-associated genome surveillance complex (BASC) which is also involved in DNA 
damage repair (Caestecker and Van de Walle, 2013).  
 
SRSF2 (SC35) 
SRSF2 is an SR protein with similar characteristics and properties to SRSF1 (Fu et al., 1992). 
SRSF2 is involved in cell cycle progression and genomic stability maintenance (Xiao et al., 
2007). As a splicing factor, SRSF2, like SRSF1, is required for recruiting the spliceosome 
complex and initiating splicing (Fu et al., 1992). Moreover, SRSF2 regulates alternative 
splicing of the tumour suppressor gene KLF6. KLF6 is a member of the Kruppel-like 
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transcription factor family. Besides the full length KLF6 protein, alternative splicing of KLF6 
generates a splice variant, SpKLF6, which arises from inclusion of a cryptic exon located 
within intron 1; this is commonly excluded in KLF6. Although the function of SpKLF6 has 
yet to be defined, its transcript contains a premature stop codon which creates a protein 
lacking the DNA binding domain. SRSF2 promotes inclusion of the cryptic exon promoting 
formation SpKLF6 at the expense of the tumour suppressor KLF6 (Shi et al., 2008). 
 
SRSF3 (SRp20) 
Another SR protein with multiple roles in transcription, alternative splicing, polyadenylation, 
nuclear transport and translation is SRFS3 (Jia et al., 2010). One study evaluating SRSF3 
expression in different stages of mammary tumorigenesis (normal, preneoplasia, neoplasia 
and tumorigenesis) showed a positive correlation between high levels of SRSF3 (both protein 
and mRNA) and severity of the disease (Stickeler et al., 1999); these two studies collectively 
suggest that oncogenic SRSF3 plays a critical role in tumour initiation and progression of the 
disease. Moreover, SRSF3 overexpression can promote cell growth, transformation and 
increases production of FoxM1b-c, Cdc25B, and PLK1 which in turn accelerates the G2/M 
phase transition and cell proliferation (Jia et al., 2010). Conversely, SRSF3 knockdown 
blocks cell cycle progression (Jia et al., 2010). Different studies have focused on the 
involvement of SRSF3 in the regulation of p53, MRP1, and FOXM1 which are strongly 
linked to cancer and also drug resistance. 
 
P53 is a tumour suppressor implicated in cell cycle regulation and maintaining DNA stability 
to prevent mutation accumulation (Yang et al., 2013). P53 activates cellular senescence and 
promotes apoptosis in cells subjected to mutations, thus, blocking any uncontrolled cell 
proliferation (Gasco et al., 2002; Tang et al., 2013). SRSF3 deficiency results in increased 
production of p53β, a splice variant of p53 that is responsible for cellular senescence activity. 
p53β arises from inclusion of exon i9 of the p53 gene, an exon that is commonly skipped. 
SRSF3 inhibits the inclusion of exon i9 by binding specific motifs within the p53 pre- mRNA 
sequence (Tang et al., 2013).   
 
SRSF3 is also a splicing regulator of multidrug resistance-associated protein 1 (MRP1) (He et 
al., 2004); expression of SRSF3 in ovarian cancer is associated with an increase in the  
number of MRP1 splice variants which may be involved in resistance towards a commonly 
used chemotherapeutic drug, doxorubicin (He et al., 2004). MRP1 is frequently 
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overexpressed in breast carcinoma leading to poor survival and resistance towards many 
antineoplastic drugs (Nooter et al., 1997; Filipits et al., 1999; Kovalev et al., 2013). 
Investigating the roles of SRSF3 in the regulation of MRP1 would potentially help to further 
understand the mechanisms of drug resistance in breast cancer. 
 
SRSF5 (SRp40) 
Another SR overexpressed in breast tumours is SRSF5 (Huang et al., 2007; Dutertre et al., 
2010); a strong association between SRSF5 expression and the production of oncogenic 
splice variants of CD44 exists in some breast tumours (Huang et al., 2007). CD44 is a cell 
surface glycoprotein receptor that has many roles particularly in cell adhesion and migration. 
Furthermore, CD44 is involved in cell growth, cell cycle regulation and cytoskeleton 
organization (Naor et al., 1997; Cheng and Sharp, 2006; Olsson et al., 2011). The CD44 gene 
has 20 exons; amongst these, 10 are constitutive exons whilst the remaining are variable 
exons (“v” exons) and reside between the constitutive exons 5 and 6 (Cheng and Sharp, 
2006). Variable exons are not included in the common CD44 protein and their expression is 
mainly reported in different tumours, including breast. Moreover, their expression profile 
correlates with estrogen receptor status (Pind and Watson, 2003; Olsson et al., 2011). 
Overexpression of SRSF5 has been linked to oncogenic variants of CD44 that arise from the 
inclusion of the variable exons v2, v3, v5, and v6 (Huang et al., 2007). V5 and v6 containing 
variants trigger the mechanisms that lead to metastasis and cell invasion (David and Manley, 
2010). Similarly to SRSF1, SRSF5 can also promote formation of the anti-apoptotic Mcl-s 
splice variant through the regulation of the alternative splicing of the Mcl-1 gene (Gautrey 
and Tyson-Capper, 2012). 
 
SRSF6 (SRp55) 
Both epidemiological and experimental evidence implicates a crucial role for estrogen and 
estrogen receptors (ER) in the progression of breast cancer; one SR protein deregulated by 
estrogen is SRSF6 (Lal et al., 2013). Estrogen reduces the abundance of SRSF6 in MCF-7 
cells resulting in exon skipping events within the corticotropin-releasing hormone receptor 
type 1(CRH-R1) gene which, in turn, affect the receptor function and inhibit estrogen-induced 
cell proliferation (Lal et al., 2013). SRSF6 also regulates alternative splicing events of CD44 
by promoting inclusion of the oncogenic variable exon v7 (Pind and Watson, 2003).  
However, SRSF6 can also act as a tumour suppressor by regulating the alternative splicing of 
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VEGFA and promoting the formation of the splice variant VEGF165b. VEGF165b is known 
to be less angiogenic compared to the common variant of VEGFA (David and Manley, 2010). 
Additionally, binding of SRSF6 onto pre-mRNA of FGFR1 (fibroblast growth factor 
receptor) leads to inclusion of exon-α; this splicing event promotes the formation of a splice 
variant of FGFR1, called  FGFR1-α, whilst preventing the production of an oncogenic splice 
variant known FGFR1-β (Ghigna et al., 2008). The FGFR1-α variant contains 
three immunoglobulin-like domains on its extracellular domain, whilst FGFR1-β lacks one of 
them. As a result, FGFR1-β can bind the ligand FGF1 (fibroblast growth factor 1) with high 
affinity, thus stimulating cell growth and promoting acquisition of cancer properties (Groth 
and Lardelli, 2002). It is interesting to note that protein levels of FGFR1-β increase in breast 
cancer cells and the ratio FGFR1-α /FGFR1-β decreases comparing to normal cells (Luqmani 
et al., 1995). 
 
SRSF10 (Tra2β) 
SRSF10 is more commonly referred to as Tra2β. A paralog form of human TRA2β gene 
exists and codes for another splicing factor known as Tra2α (Best et al., 2014). High levels of 
one homologue of Tra2β, called Tra2β1, were found in breast cancer, particularly at an 
invasive stage (Watermann et al., 2006; Dutertre et al., 2010). Tra2β1, together with YB-1 
(an RNA-binding protein which also acts as splicing factor), influences alternative splicing 
events of CD44 by promoting inclusion of both v4 and v5 exons and giving rise to oncogenic 
CD44 proteins (Watermann et al., 2006). Conversely, a study using the breast cancer cell line 
MDA-MB-231, reported that lack of both Tra2α and Tra2β misleads alternative splicing of 
the CHEK1 gene through exclusion of its exon 3; this affects the normal translational process 
of CHEK1 resulting in loss of CHEK1-mediated DNA repair and cell cycle arrest in response 
of DNA damage (Best et al., 2014). Finally, using mini-gene splicing assays reveals that 
Tra2β promotes inclusion of the 3.4 kb exon 11 of BRCA1 gene which is needed for its full 
tumour suppressor activity  (Raponi et al., 2014).  
 
HnRNPs AND THEIR ROLE IN BREAST CANCER  
HnRNPs are another well described family of splicing factors that are also involved in 
mRNA trafficking, stability and translation (He et al., 2005). HnRNPs present one, or more, 
RNA-binding domains and a domain for protein-protein interaction. HnRNPs, usually bind 
splicing silencer sequences (either ESSs or ISSs, Figure 1) preventing the splicing process 
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(Twyffels et al., 2011). Different mechanisms of splicing inhibition by hnRNPs have been 
proposed: they can compete with the SR proteins for binding sites and block interactions of 
the spliceosome with pre-mRNA. Moreover, hnRNPs can interact with each other altering the 
structure of the pre-mRNA, and in doing so making some regions inaccessible to the 
spliceosome (Cartegni et al., 2002). Numerous roles for hnRNPs in cancer development have 
been reported, including inhibition of apoptosis, promotion of EMT and angiogenesis; 
hnRNPs can control these important processes through regulation of alternative splicing 
highlighting their involvement with disease pathophysiology (Han et al., 2013). The fact that 
hnRNPs, such as hnRNP A1, A2, I and K, are overexpressed in breast cancer highlights the 
importance of assessing splicing factors status for preventing the risk of cancer associated 
variants. The following section focuses on hnRNP A1, A2, I and K, particularly focusing on 
their roles in regulating alternative splicing of both oncogenes and tumour suppressors. 
 
hnRNPA/B family 
hnRNPA/B proteins are a subfamily of hnRNPs; their expression profile is related to different 
types of cancer included breast (Patry et al., 2003; He et al., 2005; Li et al., 2009; David and 
Manley, 2010). hnRNPA/Bs include the homologous proteins hnRNPA1, A2, A3, A2/B1, 
B2, C1, C2 (Shi et al., 2003; He et al., 2005; Chaudhury et al., 2010). Amongst these, 
hnRNPA1 is one of the most well studied splicing factors (Mayeda et al., 1993; Pollard et al., 
2000; Patry et al., 2003). HnRNPA1 is overexpressed in breast tumours together with other 
members of the hnRNP family (Patry et al., 2003; He et al., 2005; Li et al., 2009). However, 
in contrast to SRSF1, hnRNPA1 can act as an onco-repressor by preventing exclusion of 
exon 11 of RON. This promotes formation of the splice variant Ron and inhibition of 
epithelial-to-mesenchymal transition (EMT) (Bonomi et al., 2013). 
 
HnRNPA1 also regulates alternative splicing of FAS (CD95). The most common FAS protein 
is a trans-membrane receptor that stimulates apoptosis after binding its ligand, FasL. A splice 
variant of FAS lacks exon 6 (E6 Fas); although E6 Fas can still compete with the common 
FAS receptor for ligand binding activity, it lacks the trans-membrane domain resulting in a 
secreted protein which is unable to activate apoptosis (David and Manley, 2010; Oh et al., 
2013). HnRNPA1 binds a splicing silencer located within exon 5 of FAS; this promotes 
inclusion of exon 6 and, in turn, decreases levels of E6 Fas (Oh et al., 2013). 
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FGFR2 is a member of the fibroblast growth factor receptor (FGFR) family which is found 
amplified in breast cancer (Moffa and Ethier, 2007). Alternative splicing of FGFR2 is also 
under the regulation of hnRNPA1. Immunoprecipitation and UV-cross-linking experiments 
reveal that hnRNPA1 can prevent production of a splice variant of FGFR2, known as 
FGFR2-IIIb, by binding an exonic splicing silencer located in proximity of exon IIIb 
(Baraniak et al., 2006). Additionally, specific single-nucleotide polymorphisms (SNPs), 
identified within intron 2 of the FGFR2 gene, are closely linked to onset of disease (Hunter et 
al., 2007). From the alternative splicing of FGFR2, two splice variants arise from the 
inclusion of either exons IIIb or IIIc; whilst exon IIIb inclusion is exclusive to epithelial cells, 
exon IIIc characterises mesenchymal tissue (Baraniak et al., 2006). A change in the ratio of 
FGFR2-IIIb and FGFR2-IIIc occurs during the progression of prostate carcinomas and in 
metastatic breast carcinoma (Baraniak et al., 2006; Zhu et al., 2009), whilst another study 
observed that  FGFR2-IIIb is overproduced in 5% of breast cancer cases (Moffa and Ethier, 
2007).  
 
It is noteworthy that the potential tumour suppressor activity of hnRNPA1 can prevent 
production of tumourigenic splice variants. However, hnRNPA1 can also act as oncoprotein 
by promoting inclusion of exon 9 of the tumour suppressor Caspase-2 (CASP2), resulting in a 
premature stop codon. This splicing event leads to production of a splice variant known as 
Casp-2S (or Ich-1S) which displays anti-apoptotic activity at the expense of the pro-apoptotic 
variant of CASP2, Ich-1L (Jiang et al., 1998; David and Manley, 2010).  
 
In addition, overexpression of hnRNPA1 can affect translation of different oncogenes; one 
study showed that hnRNPA1 promotes translation of cyclin D1 and c-Myc - both involved in 
cell proliferation - by regulating IRES (internal ribosomal entry site) activity (Jo et al., 2008). 
In turn, c-Myc stimulates transcription of hnRNPA1, resulting in a positive feedback loop 
between the two proteins (David and Manley, 2010). Interestingly, combinatory activities of 
hnRNPA1 and hnRNPA2 have been described; simultaneous overexpression of hnRNPA1 
and hnRNPA2 reduces apoptosis by stabilizing telomeric DNA in breast cancer cells, 
whereas knockdown of both proteins induces cell death (Patry et al., 2003). As splicing 
factors, both hnRNPA1 and A2 regulate alternative splicing of PKM (pyruvate kinase 
enzyme). The PKM gene can generate two splice variants arising from inclusion of either 
exon 9 (PKM1 variant) or exon 10 (PMK2 variant). One of the splice variants PMK2 
promotes aerobic glycolysis, typically exhibited by cancer cells, rather than oxidative 
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phosphorylation, which is most common in normal cells. Both hnRNPA1 and A2 can bind 
the exon 9 of PKM, repressing its inclusion, whilst promoting the production of the PMK2 
splice variant (David et al., 2010). 
 
Finally, another member of the hnRNPA/B family with relevant roles in cancer is 
hnRNPA2/B1 (Golan-Gerstl et al., 2011). Higher levels of hnRNPA2/B1 exist in breast 
tumours compared to normal breast tissue (Zhou et al., 2001).  HnRNPA2/B1, similarly to 
SRSF1, regulates alternative splicing of both RON and BIN1 promoting production of 
oncogenic and anti-apoptotic splice variants (Golan-Gerstl et al., 2011; Bonomi et al., 2013).  
 
PTB (hnRNP I) 
PTB (polypyrimidine tract binding protein) is an hnRNP protein involved in numerous stages 
of RNA processing and translation (He et al., 2014). PTB is overexpressed in transformed 
human mammary epithelial cells (HMECs) as well as the following breast cancer cell lines 
MCF-7, T47D and MDA-MB231 (He et al., 2014). Moreover, a link between PTB expression 
and malignancy of breast cancer exists, and down-regulation of PTB reduces cell 
proliferation and invasion (He et al., 2014). During alternative splicing events, PTB 
commonly binds polypyrimidine-rich tracts blocking the interaction of U2AF with the pre-
mRNA. Therefore, in most cases, PTB acts as a splicing inhibitor and promotes exon 
skipping (Brinkman, 2004; Chen and Manley, 2009; He et al., 2014). Similarly to hnRNPA1 
and A2, PTB can repress the inclusion of exon 9 of PMK, promoting the production of the 
pro-cancer splice variant PMK2 (David et al., 2010; He et al., 2014).  
 
PTB also favours the production of the oncogenic FGFR1β variant at the expense of FGFR1α 
(Ghigna et al., 2008).  Furthermore, PTB can bind a consensus motif (uridine-rich) located 
within exon 6 of the FAS gene. As a result PTB hinders association between the spliceosome 
members U2AF and snRNP U2 and the 3` splice site upstream of the exon 6. This leads to 
inhibition of exon 6 inclusion and formation of the anti-apoptotic E6 Fas (Izquierdo et al., 
2005).  
 
In addition, PTB presents anti-cancer properties by regulating alternative splicing of the 
tumour suppressor Caspase-2. PTB can repress inclusion of exon 9 of the pro-apoptotic 
Caspase-2 whilst inhibiting production of the anti-apoptotic splice variant Casp-2S (Cote et 
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al., 2001). Moreover, together with hnRNPA1, PTB can repress the inclusion of exon IIIb of 
FGFR2 by binding to intronic splicing silencer located either upstream or downstream the 
exon IIIb, thus preventing the formation of the splice variant FGFR2-IIIb (Baraniak et al., 
2006). Finally, PTB can also promote translation of the oncogene c-Myc through the binding 
of c-Myc IRES (David and Manley, 2010). 
 
HnRNP K 
HnRNP K contains a conserved K Homology RNA-binding motif (KH domain) required for 
its DNA/RNA binding-protein activity and RGG boxes needed for RNA transcription, 
processing, shuttling and also translation (Mandal et al., 2001; Tang et al., 2014). Diverse 
studies have described the transforming potential of hnRNP K and its ability in stimulating 
cell cycle progression and tumour cell viability (Venables et al., 2008; Zhou et al., 2010; 
Tang et al., 2014). Particularly interesting is the fact that expression of hnRNP K is under the 
regulation of the epidermal growth factor (EGF) (Mandal et al., 2001; Zhou et al., 2010).  
EGF activity stimulates cell proliferation by binding the epidermal growth factor receptor 
HER2 which is overexpressed in about 20-30% of breast cancer cases (Slamon et al., 1987; 
Rubin and Yarden, 2001; Jackson et al., 2013). As a splicing factor, hnRNP K regulates 
alternative splicing of the Bcl-x gene and, consequently, it promotes formation of the anti-
apoptotic variant of Bcl-x (Bcl-xL) (Han et al., 2013). Bcl-x, is a member of the apoptosis 
regulator Bcl-2 family. Similarly to Mcl-1, Bcl-x undergoes alternative splicing which can 
generate two splice variants which have opposite effects on the signalling pathway: Bcl-xs 
stimulates apoptosis whereas Bcl-xL inhibits that cellular process (Boise et al., 1993). Further 
genes involved in cell apoptosis, APAF1 and NALP1, and genes associated to breast cancer 
aggressiveness, Ostepontin and Breast cancer-associated protein (BCA3), are also targets of 
hnRNP K (Venables et al., 2008; Ortiz-Martinez et al., 2014). Finally, also the ability of 
hnRNPK to bind the promoter of c-Myc and activate transcription of the proto-oncogene in 
breast cancer cells has been described (Mandal et al., 2001). 
 
 
RNA-BINDING PROTEINS AND BREAST CANCER 
Whilst the families of SRs and hnRNP proteins are the most well characterised splicing 
factors – other RNA-binding proteins, better known for their roles in RNA transcription, 
shuttling, stability and translation also have alternative splicing regulation activities. 
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Moreover, deregulation of their expression either directly or indirectly                                                                                                                                                                                                                                                             
affect the alternative splicing of genes involved in breast cancer development. The following 
section will describe these RNA-binding proteins and their relevance to breast cancer.    
 
Sam68 (KHDRBS1, Src-associated in mitosis) 
Sam68, a member of Signal Transduction and Activation of RNA (STAR) family is activated 
by the proto-oncogene tyrosine-protein kinase (c-Src) (Fumagalli et al., 1994). Sam68 is 
overexpressed in breast cancer cell lines as well as tissues and can stimulate cell proliferation 
whilst its deficiency increases cell cycle inhibitors p27 and p21 (Song et al., 2010). Through 
the KH domain, Sam68 can bind its target RNAs. Amongst these targets, Sam68 regulates 
alternative splicing of Cyclin D1, CD44 and Bcl-X (Song et al., 2010). Sam68 promotes 
production of the proto-oncogenic splice variant cyclin D1b, resulting in an increase in the 
cyclin D1b/cyclin D1 cellular ratio (Paronetto et al., 2010). Activation of Sam68 by GTPase 
RAS, leads to CD44 exon v5 inclusion and formation of the cancer associated CD44 splice 
variant (Cheng and Sharp, 2006).  
Interestingly, Sam68 promotes expression of SRSF1 by binding to its 3’UTR (Valacca et al., 
2010); Sam68 also regulates alternative splicing of Bcl-x and promotes production of the pro-
apoptotic splice variant Bcl-x(s) (Matter et al., 2002; Paronetto et al., 2007). 
 
YB-1 (DNA-binding protein B1) 
YB-1 is a DNA/RNA binding protein, member of the Y-box family. As a splicing factor, YB-
1 is able to bind pre-mRNA of the CD44 gene specifically on A/C-rich motifs. Once bound, 
YB-1 promotes the inclusion of the variable exon v4 of CD44  (David and Manley, 2010). 
YB-1 plays also roles in both RNA transcriptional and translational processes (Swamynathan 
et al., 2002) and is involved in cell cycle control (Swamynathan et al., 2002) and genomic 
instability in breast cancer (Davies et al., 2011). YB-1 is overexpressed in breast cancer cells 
and in the surrounding tumour tissue (Janz et al., 2002; Rubinstein et al., 2002). Interestingly, 
YB-1 positively affects the expression of the breast cancer biomarkers HER2 and ERα (Fujii 
et al., 2008) and is associated with resistance towards breast cancer therapies, such as 
Lapatinib (Shibata et al., 2013); a link between YB-1 and the expression of intrinsic 
multidrug resistance gene 1 MDR1, is also documented (Mylona et al., 2014). YB-1 drives 
the expression of P-glycoprotein which blocks the permeability of drugs and toxic molecules 
into cells (Janz et al., 2002; Lin and Yamazaki, 2003). YB-1 is able to bind IRES sequence of 
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c-Myc promoting its translation (David and Manley, 2010). Overall, increased expression of 
YB-1 in human breast cancer is associated with severity of disease and poor clinical outcome 
(Bergmann et al., 2005; Evdokimova et al., 2009). 
   
FOX2 (RBM9, Fxh) 
Fox2 is another RNA-binding protein and regulator of tissue-specific splicing (Zhang et al., 
2008). Fox2 interacts with ERα and acts as corepressor by blocking the tamoxifen-mediated 
transcriptional activity of ERα (Norris et al., 2002; Zhang et al., 2008). Expression of Fox2 is 
higher in both basal and claudin low breast cancer cells compared to luminal subtype cells 
(Lapuk et al., 2010). The same study has defined claudin-low tumors, generally as triple negative 
with low levels of adherens junction genes, such as E-cadherin, and high expression of EMT 
markers (Lapuk et al., 2010). Interestingly, Fox2 can influence 50% of splicing events occurring 
in breast cancer cells included genes involved in EMT (Venables et al., 2009; Venables et al., 
2013). FGFR2 is one of the target genes of Fox2; Fox2 promotes inclusion of exon IIIb of 
FGFR2 resulting in the production of FGFR2-IIIb (Baraniak et al., 2006). Importantly, Fox2 can 
regulate alternative splicing of several factors including hnRNPs, SR proteins and itself (Yeo 
et al., 2009). Additionally, Fox2 can also complex with hnRNP H and hnRNP F for inhibiting 
FGFR2-IIIc production (Mauger et al., 2008). 
 
DAM1 ((DNA amplified in mammary carcinoma or BCAS2, SPF27) 
Amplification of the DAM1 gene has been described in MCF-7 and BT-20 breast cancer cell 
liness (Nagasaki et al., 1999; Maass et al., 2002). DAM1 protein binds both ERα, increasing 
ligand-mediated transcriptional activity of the receptor (Qi et al., 2005), and tumour 
suppressor p53, reducing its transcription activity (Kuo et al., 2009). Although DAM1 has 
been classified as a proto-oncogene, some studies in mice show that DAM1 can exert tumour 
suppressor activity through activation of BLK, a strong pro-apoptotic Bcl-2 member (Lee et 
al., 2002). As a splicing regulator, DAM1 complexes with Prp19/Pso4 and directly interacts 
with the spliceosome, although its precise role has yet to be defined (Zhang et al., 2005). 
However, Prp19 can interact with U2AF65 and directly bind to the C-terminal domain of the 
RNA Polymerase II largest subunit (CTD); this interaction promotes CTD-dependent splicing 
activation (David et al., 2011). 
 
# 
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RBM5 (RNA-binding motif protein 5, LUCA15, H37) 
Another RNA-binding protein classified as a tumour suppressor is RBM5. RBM5 promotes 
apoptosis and inhibits cell cycle (Rintala-Maki et al., 2007). The role of RBM5 as a splicing 
factor is well described; for example, RBM5 targets the pre-mRNA of the Caspase-2 gene on 
U/C rich sequences promoting exclusion of exon 9 (Fushimi et al., 2008). RBM5, like PTB, 
promotes the formation of the anti-apoptotic splice variant of FAS, E6 Fas. Whilst PTB 
hinders interaction between U2AF and U2 – RBM5 interacts with snRNP U4/U5/U6 and 
blocks recruitment of the spliceosome complex on the pre-mRNA of FAS in proximity of the 
exon 6, promoting FAS exon 6 exclusion  (Chen and Manley, 2009).  
  
HuR (Human antigen R , ELAV-like protein 1) 
HuR is a RNA-binding protein member of the ELAV like-proteins family, best known for 
their ability to stabilize mRNAs by binding AREs (AU-rich elements) (Denkert et al., 2004). 
Therefore, HuR has the capacity to regulate expression of many proto-oncogenes (Wurth, 
2012). High levels of cytoplasmic HuR are found in breast carcinoma, where it stabilizes the 
RNA of Cyclooxygenase-2 - a prognostic factor of breast cancer (Denkert et al., 2004). A 
role for HuR in regulating alternative splicing has been recently described (David and 
Manley, 2010); HuR regulates FAS by binding a splicing silencer sequence located in exon 6. 
Thus, HuR blocks U2AF65 interaction with the 3`splice site of exon 6 and as a result, HuR 
also promotes production of anti-apoptotic splice variant of FAS, E6 Fas (Izquierdo, 2008). 
 
PELP1 (Proline, glutamic acid, leucine-rich protein 1) 
PELP1 is a proto-oncogene deregulated in breast cancer and involved in cell survival, 
metastasis and drug resistance (Mann et al., 2014). Additionally, PELP1 is a nuclear 
coactivator of ERα and enhances the transcriptional activity of the receptor in response to 
estrogen (Vadlamudi et al., 2001). Depletion of PELP1 has shown to affect the expression of 
several splicing factors, revealing that PELP1 has an indirect role in regulating splicing.  
Moreover, using immunofluorescence and immunoprecipitation shows co-localisation and 
interactions of PELP1 with SRSF2 (Mann et al., 2014); PELP1 can also directly promote 
CD44 exon 4 and exon 5 exclusion. Finally, down-regulation of both PELP1 and RNA-
binding protein PRMT6 directly affects the alternative splicing of VEGF, decreasing 
VEGF165 splice variant production whilst increasing the oncogenic variants VEGF121 and 
VEGF189 (Mann et al., 2014). 
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Protein arginine methyltransferase-6 (PRMT6, CARM1 ) 
Like PELP1, PRMT6 also acts as a proto-oncogene in breast cancer (Phalke et al., 2012); 
however, more recently a controversial study has revealed the tumour suppressor activities of 
PRMT6 (Kim et al., 2013). Whilst PRMT6 is commonly known for its methyltransferase 
activity, knockdown of PRMT6 effects transcription and alternative splicing events of 
hundreds of target genes (Dowhan et al., 2012; Phalke et al., 2012). Interestingly, PRMT6 is 
also a co-activator of ERα (Dowhan et al., 2012). As a splicing factor, PRMT6 directly 
promotes exclusion of exon v5 of CD44, thus, it negatively regulates the production of the 
CD44 oncogenic splice variant. Moreover, PRMT6 regulates methylation of several splicing 
factors, therefore influencing their activity (Cheng et al., 2007; Dowhan et al., 2012).  
 
SPF45 (RBM17) 
Increased levels of SPF45 were observed in breast cancer tissues (Sampath et al., 2003). 
Additionally, different studies correlate abundance of SPF45 with the severity of tumours and 
also drug resistance (Liu et al., 2013) (Sampath et al., 2003). SPF45 acts as splicing factor by 
complexing with spliceosome members SF1, U2AF65, and SF3b155. This complex is usually 
required for the selection of 3`splice sites and for the definition of exon 6 of FAS, which 
promotes its exclusion (Corsini et al., 2007). 
 
Summary 
This review has focused on SRs, hnRNPs and other RNA-binding proteins that are 
themselves deregulated in breast cancer, including genes classified as either proto-oncogenes 
(e.g. SRSF1, SRFS3, DAM1, PELP1) or tumour suppressors (e.g. RBM, PRMT6). 
Interestingly, some of these splicing factors can simultaneously regulate alternative splicing 
of common target genes. Both cooperation and competition of splicing factors can be 
observed; for instance, the anti-apoptotic splice variant of FAS, E6 Fas, is promoted by the 
putative tumour suppressor RBM5 but negatively regulated by hnRNP A1.  
 
The advent of high throughput systems such as LISA (layered and integrated system for 
splicing annotation) - a high-throughput reverse transcription-PCR-based platform – provide 
a means to reveal hundreds of cancer-associated alternative splicing events in different 
cancers including breast (Klinck et al., 2008; Venables et al., 2008a); this experimental 
approach can be also exploited  by combining RNAi with LISA to work out how splicing 
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factors affect subsets of genes in different cellular contexts (Venables et al., 2008). With 
relevance to this review Venables et al compared a cohort of breast tumours differing in their 
estrogen receptor (ER) status and observed distinct changes in the alternative splicing events. 
ERα can alter alternative splicing of target genes by interacting and recruiting splicing machinery 
members, such as the splicing factor SF3a p120 (Auboeuf et al., 2007) and by ERα 
transcriptional coregulators (Dowhan et al., 2005). It is interesting to note that the structure of 
ERα homologous coregulators CAPER α and CAPERβ is similar to that of the splicing factor 
subunit U2AF65 (Dowhan et al., 2005). Through knockdown experiments, CAPERα can affect 
alternative splicing of the VEGF gene in a hormone-dependent way by changing the ratio VEDF-
121/VEGF-189, the most predominant VEGF splice variants together with VEGF-165 (Catena et 
al., 2007). Moreover, iCLIP combined with high-throughput sequencing is an emerging 
powerful tool to study splicing factor-RNA interactions in different cells and tissues (Konig 
et al., 2011). The technique has been adopted to determine protein-RNA interactions in vivo 
on a global scale for splicing factors such as hnRNPC, SRSF3, SRSF4 and more recently 
Tra2/Tra2(Konig et al., 2010; Anko et al., 2012; Best et al., 2014); the latter study also 
identified novel tra2-mediated splicing events that affect breast cancer cell viability (Best et 
al., 2014).    
 
In conclusion, further insights into the complexity and crosstalk within these splicing 
networks may help shed light on the mechanisms that lead to breast cancer development and 
metastasis.  
 
Funding  
This work was supported by the Royal Victoria Infirmary Breast Cancer Appeal (Reference number 
BH136312). 
 
 
References: 
Adams, J., Carder, P.J., Downey, S., Forbes, M.A., MacLennan, K., Allgar, V., Kaufman, S., Hallam, S., 
Bicknell, R., Walker, J.J., Cairnduff, F., Selby, P.J., Perren, T.J., Lansdown, M. and Banks, R.E. (2000) 
'Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and 
tissue VEGF and microvessel density and effects of tamoxifen', Cancer Res, 60(11), pp. 2898-905. 
Amin, E.M., Oltean, S., Hua, J., Gammons, M.V., Hamdollah-Zadeh, M., Welsh, G.I., Cheung, M.K., Ni, 
L., Kase, S., Rennel, E.S., Symonds, K.E., Nowak, D.G., Royer-Pokora, B., Saleem, M.A., Hagiwara, M., 
Schumacher, V.A., Harper, S.J., Hinton, D.R., Bates, D.O. and Ladomery, M.R. (2011) 'WT1 mutants 
reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing', Cancer Cell, 20(6), 
pp. 768-80. 
21 
 
Anczukow, O., Rosenberg, A.Z., Akerman, M., Das, S., Zhan, L., Karni, R., Muthuswamy, S.K. and 
Krainer, A.R. (2012) 'The splicing factor SRSF1 regulates apoptosis and proliferation to promote 
mammary epithelial cell transformation', Nat Struct Mol Biol, 19(2), pp. 220-8. 
Anko, M.L., Muller-McNicoll, M., Brandl, H., Curk, T., Gorup, C., Henry, I., Ule, J. and Neugebauer, 
K.M. (2012) 'The RNA-binding landscapes of two SR proteins reveal unique functions and binding to 
diverse RNA classes', Genome Biol, 13(3), p. R17. 
Auboeuf, D., Batsche, E., Dutertre, M., Muchardt, C. and O'Malley, B.W. (2007) 'Coregulators: 
transducing signal from transcription to alternative splicing', Trends Endocrinol Metab, 18(3), pp. 
122-9. 
Baraniak, A.P., Chen, J.R. and Garcia-Blanco, M.A. (2006) 'Fox-2 mediates epithelial cell-specific 
fibroblast growth factor receptor 2 exon choice', Mol Cell Biol, 26(4), pp. 1209-22. 
Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B. and Karni, R. (2013) 
'S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1', Cell Rep, 3(1), pp. 
103-15. 
Bergmann, S., Royer-Pokora, B., Fietze, E., Jurchott, K., Hildebrandt, B., Trost, D., Leenders, F., 
Claude, J.C., Theuring, F., Bargou, R., Dietel, M. and Royer, H.D. (2005) 'YB-1 provokes breast cancer 
through the induction of chromosomal instability that emerges from mitotic failure and centrosome 
amplification', Cancer Res, 65(10), pp. 4078-87. 
Best, A., James, K., Dalgliesh, C., Hong, E., Kheirolahi-Kouhestani, M., Curk, T., Xu, Y., Danilenko, M., 
Hussain, R., Keavney, B., Wipat, A., Klinck, R., Cowell, I.G., Cheong Lee, K., Austin, C.A., Venables, J.P., 
Chabot, B., Santibanez Koref, M., Tyson-Capper, A. and Elliott, D.J. (2014) 'Human Tra2 proteins 
jointly control a CHEK1 splicing switch among alternative and constitutive target exons', Nat 
Commun, 5, p. 4760. 
Boise, L.H., Gonzalez-Garcia, M., Postema, C.E., Ding, L., Lindsten, T., Turka, L.A., Mao, X., Nunez, G. 
and Thompson, C.B. (1993) 'bcl-x, a bcl-2-related gene that functions as a dominant regulator of 
apoptotic cell death', Cell, 74(4), pp. 597-608. 
Bonomi, S., di Matteo, A., Buratti, E., Cabianca, D.S., Baralle, F.E., Ghigna, C. and Biamonti, G. (2013) 
'HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition', 
Nucleic Acids Res, 41(18), pp. 8665-79. 
Brinkman, B.M. (2004) 'Splice variants as cancer biomarkers', Clin Biochem, 37(7), pp. 584-94. 
Caestecker, K.W. and Van de Walle, G.R. (2013) 'The role of BRCA1 in DNA double-strand repair: past 
and present', Exp Cell Res, 319(5), pp. 575-87. 
Cartegni, L., Chew, S.L. and Krainer, A.R. (2002) 'Listening to silence and understanding nonsense: 
exonic mutations that affect splicing', Nat Rev Genet, 3(4), pp. 285-98. 
Catena, R., Muniz-Medina, V., Moralejo, B., Javierre, B., Best, C.J., Emmert-Buck, M.R., Green, J.E., 
Baker, C.C. and Calvo, A. (2007) 'Increased expression of VEGF121/VEGF165-189 ratio results in a 
significant enhancement of human prostate tumor angiogenesis', Int J Cancer, 120(10), pp. 2096-
109. 
Chaudhury, A., Chander, P. and Howe, P.H. (2010) 'Heterogeneous nuclear ribonucleoproteins 
(hnRNPs) in cellular processes: Focus on hnRNP E1's multifunctional regulatory roles', RNA, 16(8), pp. 
1449-62. 
Chen, M. and Manley, J.L. (2009) 'Mechanisms of alternative splicing regulation: insights from 
molecular and genomics approaches', Nat Rev Mol Cell Biol, 10(11), pp. 741-54. 
Cheng, C. and Sharp, P.A. (2006) 'Regulation of CD44 alternative splicing by SRm160 and its potential 
role in tumor cell invasion', Mol Cell Biol, 26(1), pp. 362-70. 
Cheng, D., Cote, J., Shaaban, S. and Bedford, M.T. (2007) 'The arginine methyltransferase CARM1 
regulates the coupling of transcription and mRNA processing', Mol Cell, 25(1), pp. 71-83. 
Corsini, L., Bonnal, S., Basquin, J., Hothorn, M., Scheffzek, K., Valcarcel, J. and Sattler, M. (2007) 
'U2AF-homology motif interactions are required for alternative splicing regulation by SPF45', Nat 
Struct Mol Biol, 14(7), pp. 620-9. 
22 
 
Cote, J., Dupuis, S. and Wu, J.Y. (2001) 'Polypyrimidine track-binding protein binding downstream of 
caspase-2 alternative exon 9 represses its inclusion', J Biol Chem, 276(11), pp. 8535-43. 
Cunha, S., Lin, Y.C., Goossen, E.A., DeVette, C.I., Albertella, M.R., Thomson, S., Mulvihill, M.J. and 
Welm, A.L. (2014) 'The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-
dependent DNA methylation reprogramming', Cell Rep, 6(1), pp. 141-54. 
Das, S., Anczukow, O., Akerman, M. and Krainer, A.R. (2012) 'Oncogenic splicing factor SRSF1 is a 
critical transcriptional target of MYC', Cell Rep, 1(2), pp. 110-7. 
David, C.J., Boyne, A.R., Millhouse, S.R. and Manley, J.L. (2011) 'The RNA polymerase II C-terminal 
domain promotes splicing activation through recruitment of a U2AF65-Prp19 complex', Genes Dev, 
25(9), pp. 972-83. 
David, C.J., Chen, M., Assanah, M., Canoll, P. and Manley, J.L. (2010) 'HnRNP proteins controlled by c-
Myc deregulate pyruvate kinase mRNA splicing in cancer', Nature, 463(7279), pp. 364-8. 
David, C.J. and Manley, J.L. (2010) 'Alternative pre-mRNA splicing regulation in cancer: pathways and 
programs unhinged', Genes Dev, 24(21), pp. 2343-64. 
Davies, A.H., Barrett, I., Pambid, M.R., Hu, K., Stratford, A.L., Freeman, S., Berquin, I.M., Pelech, S., 
Hieter, P., Maxwell, C. and Dunn, S.E. (2011) 'YB-1 evokes susceptibility to cancer through cytokinesis 
failure, mitotic dysfunction and HER2 amplification', Oncogene, 30(34), pp. 3649-60. 
De Craene, B. and Berx, G. (2013) 'Regulatory networks defining EMT during cancer initiation and 
progression', Nat Rev Cancer, 13(2), pp. 97-110. 
Denkert, C., Weichert, W., Winzer, K.J., Muller, B.M., Noske, A., Niesporek, S., Kristiansen, G., Guski, 
H., Dietel, M. and Hauptmann, S. (2004) 'Expression of the ELAV-like protein HuR is associated with 
higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma', Clin 
Cancer Res, 10(16), pp. 5580-6. 
Dowhan, D.H., Harrison, M.J., Eriksson, N.A., Bailey, P., Pearen, M.A., Fuller, P.J., Funder, J.W., 
Simpson, E.R., Leedman, P.J., Tilley, W.D., Brown, M.A., Clarke, C.L. and Muscat, G.E. (2012) 'Protein 
arginine methyltransferase 6-dependent gene expression and splicing: association with breast 
cancer outcomes', Endocr Relat Cancer, 19(4), pp. 509-26. 
Dowhan, D.H., Hong, E.P., Auboeuf, D., Dennis, A.P., Wilson, M.M., Berget, S.M. and O'Malley, B.W. 
(2005) 'Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related 
proteins CAPERalpha and CAPERbeta', Mol Cell, 17(3), pp. 429-39. 
Drabsch, Y., Robert, R.G. and Gonda, T.J. (2010) 'MYB suppresses differentiation and apoptosis of 
human breast cancer cells', Breast Cancer Res, 12(4), p. R55. 
Dutertre, M., Vagner, S. and Auboeuf, D. (2010) 'Alternative splicing and breast cancer', RNA Biol, 
7(4), pp. 403-11. 
Evdokimova, V., Tognon, C., Ng, T., Ruzanov, P., Melnyk, N., Fink, D., Sorokin, A., Ovchinnikov, L.P., 
Davicioni, E., Triche, T.J. and Sorensen, P.H. (2009) 'Translational activation of snail1 and other 
developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal 
transition', Cancer Cell, 15(5), pp. 402-15. 
Filipits, M., Malayeri, R., Suchomel, R.W., Pohl, G., Stranzl, T., Dekan, G., Kaider, A., Stiglbauer, W., 
Depisch, D. and Pirker, R. (1999) 'Expression of the multidrug resistance protein (MRP1) in breast 
cancer', Anticancer Res, 19(6B), pp. 5043-9. 
Fu, X.D. (1995) 'The superfamily of arginine/serine-rich splicing factors', RNA, 1(7), pp. 663-80. 
Fu, X.D., Mayeda, A., Maniatis, T. and Krainer, A.R. (1992) 'General splicing factors SF2 and SC35 
have equivalent activities in vitro, and both affect alternative 5' and 3' splice site selection', Proc Natl 
Acad Sci U S A, 89(23), pp. 11224-8. 
Fujii, T., Kawahara, A., Basaki, Y., Hattori, S., Nakashima, K., Nakano, K., Shirouzu, K., Kohno, K., 
Yanagawa, T., Yamana, H., Nishio, K., Ono, M., Kuwano, M. and Kage, M. (2008) 'Expression of HER2 
and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human 
breast cancers', Cancer Res, 68(5), pp. 1504-12. 
Fumagalli, S., Totty, N.F., Hsuan, J.J. and Courtneidge, S.A. (1994) 'A target for Src in mitosis', Nature, 
368(6474), pp. 871-4. 
23 
 
Fushimi, K., Ray, P., Kar, A., Wang, L., Sutherland, L.C. and Wu, J.Y. (2008) 'Up-regulation of the 
proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5', Proc Natl Acad Sci 
U S A, 105(41), pp. 15708-13. 
Gasco, M., Shami, S. and Crook, T. (2002) 'The p53 pathway in breast cancer', Breast Cancer Res, 
4(2), pp. 70-6. 
Gautrey, H.L. and Tyson-Capper, A.J. (2012) 'Regulation of Mcl-1 by SRSF1 and SRSF5 in cancer cells', 
PLoS One, 7(12), p. e51497. 
Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U. and Prendergast, G.C. (1999) 'Mechanism for 
elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss of function 
of Bin1 in melanoma', Proc Natl Acad Sci U S A, 96(17), pp. 9689-94. 
Ge, K., Duhadaway, J., Sakamuro, D., Wechsler-Reya, R., Reynolds, C. and Prendergast, G.C. (2000) 
'Losses of the tumor suppressor BIN1 in breast carcinoma are frequent and reflect deficits in 
programmed cell death capacity', Int J Cancer, 85(3), pp. 376-83. 
Ghigna, C., Giordano, S., Shen, H., Benvenuto, F., Castiglioni, F., Comoglio, P.M., Green, M.R., Riva, S. 
and Biamonti, G. (2005) 'Cell motility is controlled by SF2/ASF through alternative splicing of the Ron 
protooncogene', Mol Cell, 20(6), pp. 881-90. 
Ghigna, C., Valacca, C. and Biamonti, G. (2008) 'Alternative splicing and tumor progression', Curr 
Genomics, 9(8), pp. 556-70. 
Golan-Gerstl, R., Cohen, M., Shilo, A., Suh, S.S., Bakacs, A., Coppola, L. and Karni, R. (2011) 'Splicing 
factor hnRNP A2/B1 regulates tumor suppressor gene splicing and is an oncogenic driver in 
glioblastoma', Cancer Res, 71(13), pp. 4464-72. 
Goncalves, V., Theisen, P., Antunes, O., Medeira, A., Ramos, J.S., Jordan, P. and Isidro, G. (2009) 'A 
missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing enhancer motif 
and causes pathogenic skipping of exon 14', Mutat Res, 662(1-2), pp. 33-6. 
Grosso, A.R., Martins, S. and Carmo-Fonseca, M. (2008) 'The emerging role of splicing factors in 
cancer', EMBO Rep, 9(11), pp. 1087-93. 
Groth, C. and Lardelli, M. (2002) 'The structure and function of vertebrate fibroblast growth factor 
receptor 1', Int J Dev Biol, 46(4), pp. 393-400. 
Han, N., Li, W. and Zhang, M. (2013) 'The function of the RNA-binding protein hnRNP in cancer 
metastasis', J Cancer Res Ther, 9 Suppl, pp. S129-34. 
He, X., Arslan, A.D., Ho, T.T., Yuan, C., Stampfer, M.R. and Beck, W.T. (2014) 'Involvement of 
polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant 
properties', Oncogenesis, 3, p. e84. 
He, X., Ee, P.L., Coon, J.S. and Beck, W.T. (2004) 'Alternative splicing of the multidrug resistance 
protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice 
variants and is associated with increased expression of the splicing factors PTB and SRp20', Clin 
Cancer Res, 10(14), pp. 4652-60. 
He, Y., Brown, M.A., Rothnagel, J.A., Saunders, N.A. and Smith, R. (2005) 'Roles of heterogeneous 
nuclear ribonucleoproteins A and B in cell proliferation', J Cell Sci, 118(Pt 14), pp. 3173-83. 
Ho, K.Y., Kalle, W.H., Lo, T.H., Lam, W.Y. and Tang, C.M. (1999) 'Reduced expression of APC and DCC 
gene protein in breast cancer', Histopathology, 35(3), pp. 249-56. 
Huang, C.S., Shen, C.Y., Wang, H.W., Wu, P.E. and Cheng, C.W. (2007) 'Increased expression of SRp40 
affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human 
breast cancer', Clin Chim Acta, 384(1-2), pp. 69-74. 
Hunter, D.J., Kraft, P., Jacobs, K.B., Cox, D.G., Yeager, M., Hankinson, S.E., Wacholder, S., Wang, Z., 
Welch, R., Hutchinson, A., Wang, J., Yu, K., Chatterjee, N., Orr, N., Willett, W.C., Colditz, G.A., Ziegler, 
R.G., Berg, C.D., Buys, S.S., McCarty, C.A., Feigelson, H.S., Calle, E.E., Thun, M.J., Hayes, R.B., Tucker, 
M., Gerhard, D.S., Fraumeni, J.F., Jr., Hoover, R.N., Thomas, G. and Chanock, S.J. (2007) 'A genome-
wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal 
breast cancer', Nat Genet, 39(7), pp. 870-4. 
24 
 
Izquierdo, J.M., Majos, N., Bonnal, S., Martinez, C., Castelo, R., Guigo, R., Bilbao, D. and Valcarcel, J. 
(2005) 'Regulation of Fas alternative splicing by antagonistic effects of TIA-1 and PTB on exon 
definition', Mol Cell, 19(4), pp. 475-84. 
Jackson, C., Browell, D., Gautrey, H. and Tyson-Capper, A. (2013) 'Clinical Significance of HER-2 Splice 
Variants in Breast Cancer Progression and Drug Resistance', Int J Cell Biol, 2013, p. 973584. 
Janz, M., Harbeck, N., Dettmar, P., Berger, U., Schmidt, A., Jurchott, K., Schmitt, M. and Royer, H.D. 
(2002) 'Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent 
of clinically relevant tumor biologic factors HER2, uPA and PAI-1', Int J Cancer, 97(3), pp. 278-82. 
Jia, R., Li, C., McCoy, J.P., Deng, C.X. and Zheng, Z.M. (2010) 'SRp20 is a proto-oncogene critical for 
cell proliferation and tumor induction and maintenance', Int J Biol Sci, 6(7), pp. 806-26. 
Jiang, Z.H., Zhang, W.J., Rao, Y. and Wu, J.Y. (1998) 'Regulation of Ich-1 pre-mRNA alternative splicing 
and apoptosis by mammalian splicing factors', Proc Natl Acad Sci U S A, 95(16), pp. 9155-60. 
Jo, O.D., Martin, J., Bernath, A., Masri, J., Lichtenstein, A. and Gera, J. (2008) 'Heterogeneous nuclear 
ribonucleoprotein A1 regulates cyclin D1 and c-myc internal ribosome entry site function through 
Akt signaling', J Biol Chem, 283(34), pp. 23274-87. 
Karni, R., de Stanchina, E., Lowe, S.W., Sinha, R., Mu, D. and Krainer, A.R. (2007) 'The gene encoding 
the splicing factor SF2/ASF is a proto-oncogene', Nat Struct Mol Biol, 14(3), pp. 185-93. 
Kim, C.J., Nishi, K., Isono, T., Okuyama, Y., Tambe, Y., Okada, Y. and Inoue, H. (2009) 'Cyclin D1b 
variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells', 
Mol Carcinog, 48(10), pp. 953-64. 
Kim, N.H., Kim, S.N., Seo, D.W., Han, J.W. and Kim, Y.K. (2013) 'PRMT6 overexpression upregulates 
TSP-1 and downregulates MMPs: its implication in motility and invasion', Biochem Biophys Res 
Commun, 432(1), pp. 60-5. 
Knopfova, L., Benes, P., Pekarcikova, L., Hermanova, M., Masarik, M., Pernicova, Z., Soucek, K. and 
Smarda, J. (2012) 'c-Myb regulates matrix metalloproteinases 1/9, and cathepsin D: implications for 
matrix-dependent breast cancer cell invasion and metastasis', Mol Cancer, 11, p. 15. 
Konig, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D.J., Luscombe, N.M. and Ule, J. 
(2010) 'iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution', 
Nat Struct Mol Biol, 17(7), pp. 909-15. 
Konig, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D.J., Luscombe, N.M. and Ule, J. 
(2011) 'iCLIP--transcriptome-wide mapping of protein-RNA interactions with individual nucleotide 
resolution', J Vis Exp, (50). 
Kovalev, A.A., Tsvetaeva, D.A. and Grudinskaja, T.V. (2013) 'Role of ABC-cassette transporters 
(MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in 
patients with early and metastatic breast cancer', Exp Oncol, 35(4), pp. 287-90. 
Krainer, A.R., Conway, G.C. and Kozak, D. (1990) 'The essential pre-mRNA splicing factor SF2 
influences 5' splice site selection by activating proximal sites', Cell, 62(1), pp. 35-42. 
Kumar, A., Baker, S.J., Lee, C.M. and Reddy, E.P. (2003) 'Molecular mechanisms associated with the 
regulation of apoptosis by the two alternatively spliced products of c-Myb', Mol Cell Biol, 23(18), pp. 
6631-45. 
Kuo, P.C., Tsao, Y.P., Chang, H.W., Chen, P.H., Huang, C.W., Lin, S.T., Weng, Y.T., Tsai, T.C., Shieh, S.Y. 
and Chen, S.L. (2009) 'Breast cancer amplified sequence 2, a novel negative regulator of the p53 
tumor suppressor', Cancer Res, 69(23), pp. 8877-85. 
Lal, S., Allan, A., Markovic, D., Walker, R., Macartney, J., Europe-Finner, N., Tyson-Capper, A. and 
Grammatopoulos, D.K. (2013) 'Estrogen alters the splicing of type 1 corticotropin-releasing hormone 
receptor in breast cancer cells', Sci Signal, 6(282), p. ra53. 
Lapuk, A., Marr, H., Jakkula, L., Pedro, H., Bhattacharya, S., Purdom, E., Hu, Z., Simpson, K., Pachter, 
L., Durinck, S., Wang, N., Parvin, B., Fontenay, G., Speed, T., Garbe, J., Stampfer, M., Bayandorian, H., 
Dorton, S., Clark, T.A., Schweitzer, A., Wyrobek, A., Feiler, H., Spellman, P., Conboy, J. and Gray, J.W. 
(2010) 'Exon-level microarray analyses identify alternative splicing programs in breast cancer', Mol 
Cancer Res, 8(7), pp. 961-74. 
25 
 
Lee, S., Ha, S., Chung, M., Kim, Y. and Choi, Y. (2002) 'Mouse DAM1 regulates pro-apoptotic activity 
of BLK in mammary epithelial cells', Cancer Lett, 188(1-2), pp. 121-6. 
Li, B.D., Liu, L., Dawson, M. and De Benedetti, A. (1997) 'Overexpression of eukaryotic initiation 
factor 4E (eIF4E) in breast carcinoma', Cancer, 79(12), pp. 2385-90. 
Li, S., Xu, H., Ding, H., Huang, Y., Cao, X., Yang, G., Li, J., Xie, Z., Meng, Y., Li, X., Zhao, Q., Shen, B. and 
Shao, N. (2009) 'Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX', J 
Pathol, 218(3), pp. 327-36. 
Li, X. and Manley, J.L. (2005) 'Inactivation of the SR protein splicing factor ASF/SF2 results in genomic 
instability', Cell, 122(3), pp. 365-78. 
Lin, J.H. and Yamazaki, M. (2003) 'Role of P-glycoprotein in pharmacokinetics: clinical implications', 
Clin Pharmacokinet, 42(1), pp. 59-98. 
Liu, Y., Conaway, L., Rutherford Bethard, J., Al-Ayoubi, A.M., Thompson Bradley, A., Zheng, H., Weed, 
S.A. and Eblen, S.T. (2013) 'Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by 
Clk1 regulates its splice site utilization, cell migration and invasion', Nucleic Acids Res, 41(9), pp. 
4949-62. 
Lixia, M., Zhijian, C., Chao, S., Chaojiang, G. and Congyi, Z. (2007) 'Alternative splicing of breast 
cancer associated gene BRCA1 from breast cancer cell line', J Biochem Mol Biol, 40(1), pp. 15-21. 
Luqmani, Y.A., Mortimer, C., Yiangou, C., Johnston, C.L., Bansal, G.S., Sinnett, D., Law, M. and 
Coombes, R.C. (1995) 'Expression of 2 variant forms of fibroblast growth factor receptor 1 in human 
breast', Int J Cancer, 64(4), pp. 274-9. 
Maass, N., Rosel, F., Schem, C., Hitomi, J., Jonat, W. and Nagasaki, K. (2002) 'Amplification of the 
BCAS2 gene at chromosome 1p13.3-21 in human primary breast cancer', Cancer Lett, 185(2), pp. 
219-23. 
Mandal, M., Vadlamudi, R., Nguyen, D., Wang, R.A., Costa, L., Bagheri-Yarmand, R., Mendelsohn, J. 
and Kumar, R. (2001) 'Growth factors regulate heterogeneous nuclear ribonucleoprotein K 
expression and function', J Biol Chem, 276(13), pp. 9699-704. 
Manley, J.L. and Tacke, R. (1996) 'SR proteins and splicing control', Genes Dev, 10(13), pp. 1569-79. 
Mann, M., Zou, Y., Chen, Y., Brann, D. and Vadlamudi, R. (2014) 'PELP1 oncogenic functions involve 
alternative splicing via PRMT6', Mol Oncol, 8(2), pp. 389-400. 
Matter, N., Herrlich, P. and Konig, H. (2002) 'Signal-dependent regulation of splicing via 
phosphorylation of Sam68', Nature, 420(6916), pp. 691-5. 
Mauger, D.M., Lin, C. and Garcia-Blanco, M.A. (2008) 'hnRNP H and hnRNP F complex with Fox2 to 
silence fibroblast growth factor receptor 2 exon IIIc', Mol Cell Biol, 28(17), pp. 5403-19. 
Mayeda, A., Helfman, D.M. and Krainer, A.R. (1993) 'Modulation of exon skipping and inclusion by 
heterogeneous nuclear ribonucleoprotein A1 and pre-mRNA splicing factor SF2/ASF', Mol Cell Biol, 
13(5), pp. 2993-3001. 
McManus, C.J. and Graveley, B.R. (2011) 'RNA structure and the mechanisms of alternative splicing', 
Curr Opin Genet Dev, 21(4), pp. 373-9. 
Moffa, A.B. and Ethier, S.P. (2007) 'Differential signal transduction of alternatively spliced FGFR2 
variants expressed in human mammary epithelial cells', J Cell Physiol, 210(3), pp. 720-31. 
Mylona, E., Melissaris, S., Giannopoulou, I., Theohari, I., Papadimitriou, C., Keramopoulos, A. and 
Nakopoulou, L. (2014) 'Y-box-binding protein 1 (YB1) in breast carcinomas: relation to aggressive 
tumor phenotype and identification of patients at high risk for relapse', Eur J Surg Oncol, 40(3), pp. 
289-96. 
Nagasaki, K., Maass, N., Manabe, T., Hanzawa, H., Tsukada, T., Kikuchi, K. and Yamaguchi, K. (1999) 
'Identification of a novel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast 
cancer cell lines', Cancer Lett, 140(1-2), pp. 219-26. 
Naor, D., Sionov, R.V. and Ish-Shalom, D. (1997) 'CD44: structure, function, and association with the 
malignant process', Adv Cancer Res, 71, pp. 241-319. 
Nooter, K., Brutel de la Riviere, G., Look, M.P., van Wingerden, K.E., Henzen-Logmans, S.C., Scheper, 
R.J., Flens, M.J., Klijn, J.G., Stoter, G. and Foekens, J.A. (1997) 'The prognostic significance of 
26 
 
expression of the multidrug resistance-associated protein (MRP) in primary breast cancer', Br J 
Cancer, 76(4), pp. 486-93. 
Norris, J.D., Fan, D., Sherk, A. and McDonnell, D.P. (2002) 'A negative coregulator for the human ER', 
Mol Endocrinol, 16(3), pp. 459-68. 
O'Rourke, J.P. and Ness, S.A. (2008) 'Alternative RNA splicing produces multiple forms of c-Myb with 
unique transcriptional activities', Mol Cell Biol, 28(6), pp. 2091-101. 
Oh, H., Lee, E., Jang, H.N., Lee, J., Moon, H., Sheng, Z., Jun, Y., Loh, T.J., Cho, S., Zhou, J., Green, M.R., 
Zheng, X. and Shen, H. (2013) 'hnRNP A1 contacts exon 5 to promote exon 6 inclusion of apoptotic 
Fas gene', Apoptosis, 18(7), pp. 825-35. 
Olshavsky, N.A., Comstock, C.E., Schiewer, M.J., Augello, M.A., Hyslop, T., Sette, C., Zhang, J., 
Parysek, L.M. and Knudsen, K.E. (2010) 'Identification of ASF/SF2 as a critical, allele-specific effector 
of the cyclin D1b oncogene', Cancer Res, 70(10), pp. 3975-84. 
Olsson, E., Honeth, G., Bendahl, P.O., Saal, L.H., Gruvberger-Saal, S., Ringner, M., Vallon-Christersson, 
J., Jonsson, G., Holm, K., Lovgren, K., Ferno, M., Grabau, D., Borg, A. and Hegardt, C. (2011) 'CD44 
isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and 
cancer stem cell markers', BMC Cancer, 11, p. 418. 
Orban, T.I. and Olah, E. (2003) 'Emerging roles of BRCA1 alternative splicing', Mol Pathol, 56(4), pp. 
191-7. 
Ortiz-Martinez, F., Perez-Balaguer, A., Ciprian, D., Andres, L., Ponce, J., Adrover, E., Sanchez-Paya, J., 
Aranda, F.I., Lerma, E. and Peiro, G. (2014) 'Association of increased osteopontin and splice variant-c 
mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and 
recurrence', Hum Pathol, 45(3), pp. 504-12. 
Paronetto, M.P., Achsel, T., Massiello, A., Chalfant, C.E. and Sette, C. (2007) 'The RNA-binding protein 
Sam68 modulates the alternative splicing of Bcl-x', J Cell Biol, 176(7), pp. 929-39. 
Paronetto, M.P., Cappellari, M., Busa, R., Pedrotti, S., Vitali, R., Comstock, C., Hyslop, T., Knudsen, 
K.E. and Sette, C. (2010) 'Alternative splicing of the cyclin D1 proto-oncogene is regulated by the 
RNA-binding protein Sam68', Cancer Res, 70(1), pp. 229-39. 
Patry, C., Bouchard, L., Labrecque, P., Gendron, D., Lemieux, B., Toutant, J., Lapointe, E., Wellinger, 
R. and Chabot, B. (2003) 'Small interfering RNA-mediated reduction in heterogeneous nuclear 
ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal 
mortal cell lines', Cancer Res, 63(22), pp. 7679-88. 
Phalke, S., Mzoughi, S., Bezzi, M., Jennifer, N., Mok, W.C., Low, D.H., Thike, A.A., Kuznetsov, V.A., 
Tan, P.H., Voorhoeve, P.M. and Guccione, E. (2012) 'p53-Independent regulation of p21Waf1/Cip1 
expression and senescence by PRMT6', Nucleic Acids Res, 40(19), pp. 9534-42. 
Pind, M.T. and Watson, P.H. (2003) 'SR protein expression and CD44 splicing pattern in human breast 
tumours', Breast Cancer Res Treat, 79(1), pp. 75-82. 
Pollard, A.J., Sparey, C., Robson, S.C., Krainer, A.R. and Europe-Finner, G.N. (2000) 'Spatio-temporal 
expression of the trans-acting splicing factors SF2/ASF and heterogeneous ribonuclear proteins 
A1/A1B in the myometrium of the pregnant human uterus: a molecular mechanism for regulating 
regional protein isoform expression in vivo', J Clin Endocrinol Metab, 85(5), pp. 1928-36. 
Qi, C., Zhu, Y.T., Chang, J., Yeldandi, A.V., Rao, M.S. and Zhu, Y.J. (2005) 'Potentiation of estrogen 
receptor transcriptional activity by breast cancer amplified sequence 2', Biochem Biophys Res 
Commun, 328(2), pp. 393-8. 
Quintana, A.M., Liu, F., O'Rourke, J.P. and Ness, S.A. (2011) 'Identification and regulation of c-Myb 
target genes in MCF-7 cells', BMC Cancer, 11, p. 30. 
Raponi, M., Smith, L.D., Silipo, M., Stuani, C., Buratti, E. and Baralle, D. (2014) 'BRCA1 exon 11 a 
model of long exon splicing regulation', RNA Biol, 11(4). 
Rintala-Maki, N.D., Goard, C.A., Langdon, C.E., Wall, V.E., Traulsen, K.E., Morin, C.D., Bonin, M. and 
Sutherland, L.C. (2007) 'Expression of RBM5-related factors in primary breast tissue', J Cell Biochem, 
100(6), pp. 1440-58. 
Roy, P.G. and Thompson, A.M. (2006) 'Cyclin D1 and breast cancer', Breast, 15(6), pp. 718-27. 
27 
 
Rubin, I. and Yarden, Y. (2001) 'The basic biology of HER2', Ann Oncol, 12 Suppl 1, pp. S3-8. 
Rubinstein, D.B., Stortchevoi, A., Boosalis, M., Ashfaq, R. and Guillaume, T. (2002) 'Overexpression of 
DNA-binding protein B gene product in breast cancer as detected by in vitro-generated 
combinatorial human immunoglobulin libraries', Cancer Res, 62(17), pp. 4985-91. 
Sampath, J., Long, P.R., Shepard, R.L., Xia, X., Devanarayan, V., Sandusky, G.E., Perry, W.L., 3rd, 
Dantzig, A.H., Williamson, M., Rolfe, M. and Moore, R.E. (2003) 'Human SPF45, a splicing factor, has 
limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-
resistant phenotype to cells', Am J Pathol, 163(5), pp. 1781-90. 
Scheper, G.C., Parra, J.L., Wilson, M., Van Kollenburg, B., Vertegaal, A.C., Han, Z.G. and Proud, C.G. 
(2003) 'The N and C termini of the splice variants of the human mitogen-activated protein kinase-
interacting kinase Mnk2 determine activity and localization', Mol Cell Biol, 23(16), pp. 5692-705. 
Schnelzer, A., Prechtel, D., Knaus, U., Dehne, K., Gerhard, M., Graeff, H., Harbeck, N., Schmitt, M. and 
Lengyel, E. (2000) 'Rac1 in human breast cancer: overexpression, mutation analysis, and 
characterization of a new isoform, Rac1b', Oncogene, 19(26), pp. 3013-20. 
Shi, J., Hu, Z., Pabon, K. and Scotto, K.W. (2008) 'Caffeine regulates alternative splicing in a subset of 
cancer-associated genes: a role for SC35', Mol Cell Biol, 28(2), pp. 883-95. 
Shi, S.T., Yu, G.Y. and Lai, M.M. (2003) 'Multiple type A/B heterogeneous nuclear ribonucleoproteins 
(hnRNPs) can replace hnRNP A1 in mouse hepatitis virus RNA synthesis', J Virol, 77(19), pp. 10584-
93. 
Shibata, T., Kan, H., Murakami, Y., Ureshino, H., Watari, K., Kawahara, A., Kage, M., Hattori, S., Ono, 
M. and Kuwano, M. (2013) 'Y-box binding protein-1 contributes to both HER2/ErbB2 expression and 
lapatinib sensitivity in human gastric cancer cells', Mol Cancer Ther, 12(5), pp. 737-46. 
Shimoni-Sebag, A., Lebenthal-Loinger, I., Zender, L. and Karni, R. (2013) 'RRM1 domain of the splicing 
oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation', 
Carcinogenesis, 34(11), pp. 2498-504. 
Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L. (1987) 'Human breast 
cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene', Science, 
235(4785), pp. 177-82. 
Song, L., Wang, L., Li, Y., Xiong, H., Wu, J., Li, J. and Li, M. (2010) 'Sam68 up-regulation correlates 
with, and its down-regulation inhibits, proliferation and tumourigenicity of breast cancer cells', J 
Pathol, 222(3), pp. 227-37. 
Soni, A., Akcakanat, A., Singh, G., Luyimbazi, D., Zheng, Y., Kim, D., Gonzalez-Angulo, A. and Meric-
Bernstam, F. (2008) 'eIF4E knockdown decreases breast cancer cell growth without activating Akt 
signaling', Mol Cancer Ther, 7(7), pp. 1782-8. 
Srebrow, A. and Kornblihtt, A.R. (2006) 'The connection between splicing and cancer', J Cell Sci, 
119(Pt 13), pp. 2635-41. 
Stickeler, E., Kittrell, F., Medina, D. and Berget, S.M. (1999) 'Stage-specific changes in SR splicing 
factors and alternative splicing in mammary tumorigenesis', Oncogene, 18(24), pp. 3574-82. 
Swamynathan, S.K., Varma, B.R., Weber, K.T. and Guntaka, R.V. (2002) 'Targeted disruption of one 
allele of the Y-box protein gene, Chk-YB-1b, in DT40 cells results in major defects in cell cycle', 
Biochem Biophys Res Commun, 296(2), pp. 451-7. 
Tammaro, C., Raponi, M., Wilson, D.I. and Baralle, D. (2012) 'BRCA1 exon 11 alternative splicing, 
multiple functions and the association with cancer', Biochem Soc Trans, 40(4), pp. 768-72. 
Tang, F., Li, W., Chen, Y., Wang, D., Han, J. and Liu, D. (2014) 'Downregulation of hnRNP K by RNAi 
inhibits growth of human lung carcinoma cells', Oncol Lett, 7(4), pp. 1073-1077. 
Tang, Y., Horikawa, I., Ajiro, M., Robles, A.I., Fujita, K., Mondal, A.M., Stauffer, J.K., Zheng, Z.M. and 
Harris, C.C. (2013) 'Downregulation of splicing factor SRSF3 induces p53beta, an alternatively spliced 
isoform of p53 that promotes cellular senescence', Oncogene, 32(22), pp. 2792-8. 
Thorner, A.R., Parker, J.S., Hoadley, K.A. and Perou, C.M. (2010) 'Potential tumor suppressor role for 
the c-Myb oncogene in luminal breast cancer', PLoS One, 5(10), p. e13073. 
28 
 
Twyffels, L., Gueydan, C. and Kruys, V. (2011) 'Shuttling SR proteins: more than splicing factors', FEBS 
J, 278(18), pp. 3246-55. 
Vadlamudi, R.K., Wang, R.A., Mazumdar, A., Kim, Y., Shin, J., Sahin, A. and Kumar, R. (2001) 
'Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor 
alpha', J Biol Chem, 276(41), pp. 38272-9. 
Valacca, C., Bonomi, S., Buratti, E., Pedrotti, S., Baralle, F.E., Sette, C., Ghigna, C. and Biamonti, G. 
(2010) 'Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay 
of the SF2/ASF proto-oncogene', J Cell Biol, 191(1), pp. 87-99. 
Venables, J.P., Koh, C.S., Froehlich, U., Lapointe, E., Couture, S., Inkel, L., Bramard, A., Paquet, E.R., 
Watier, V., Durand, M., Lucier, J.F., Gervais-Bird, J., Tremblay, K., Prinos, P., Klinck, R., Elela, S.A. and 
Chabot, B. (2008) 'Multiple and specific mRNA processing targets for the major human hnRNP 
proteins', Mol Cell Biol, 28(19), pp. 6033-43. 
Watermann, D.O., Tang, Y., Zur Hausen, A., Jager, M., Stamm, S. and Stickeler, E. (2006) 'Splicing 
factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the 
CD44 gene', Cancer Res, 66(9), pp. 4774-80. 
Wurth, L. (2012) 'Versatility of RNA-Binding Proteins in Cancer', Comp Funct Genomics, 2012, p. 
178525. 
Xiao, R., Sun, Y., Ding, J.H., Lin, S., Rose, D.W., Rosenfeld, M.G., Fu, X.D. and Li, X. (2007) 'Splicing 
regulator SC35 is essential for genomic stability and cell proliferation during mammalian 
organogenesis', Mol Cell Biol, 27(15), pp. 5393-402. 
Yamnik, R.L., Digilova, A., Davis, D.C., Brodt, Z.N., Murphy, C.J. and Holz, M.K. (2009) 'S6 kinase 1 
regulates estrogen receptor alpha in control of breast cancer cell proliferation', J Biol Chem, 284(10), 
pp. 6361-9. 
Yang, P., Du, C.W., Kwan, M., Liang, S.X. and Zhang, G.J. (2013) 'The impact of p53 in predicting 
clinical outcome of breast cancer patients with visceral metastasis', Sci Rep, 3, p. 2246. 
Yeo, G.W., Coufal, N.G., Liang, T.Y., Peng, G.E., Fu, X.D. and Gage, F.H. (2009) 'An RNA code for the 
FOX2 splicing regulator revealed by mapping RNA-protein interactions in stem cells', Nat Struct Mol 
Biol, 16(2), pp. 130-7. 
Zhang, C., Zhang, Z., Castle, J., Sun, S., Johnson, J., Krainer, A.R. and Zhang, M.Q. (2008) 'Defining the 
regulatory network of the tissue-specific splicing factors Fox-1 and Fox-2', Genes Dev, 22(18), pp. 
2550-63. 
Zhang, N., Kaur, R., Lu, X., Shen, X., Li, L. and Legerski, R.J. (2005) 'The Pso4 mRNA splicing and DNA 
repair complex interacts with WRN for processing of DNA interstrand cross-links', J Biol Chem, 
280(49), pp. 40559-67. 
Zhou, C., Licciulli, S., Avila, J.L., Cho, M., Troutman, S., Jiang, P., Kossenkov, A.V., Showe, L.C., Liu, Q., 
Vachani, A., Albelda, S.M. and Kissil, J.L. (2013) 'The Rac1 splice form Rac1b promotes K-ras-induced 
lung tumorigenesis', Oncogene, 32(7), pp. 903-9. 
Zhou, J., Allred, D.C., Avis, I., Martinez, A., Vos, M.D., Smith, L., Treston, A.M. and Mulshine, J.L. 
(2001) 'Differential expression of the early lung cancer detection marker, heterogeneous nuclear 
ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer', Breast 
Cancer Res Treat, 66(3), pp. 217-24. 
Zhou, R., Shanas, R., Nelson, M.A., Bhattacharyya, A. and Shi, J. (2010) 'Increased expression of the 
heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant 
p53', Int J Cancer, 126(2), pp. 395-404. 
Zhu, X., Asa, S.L. and Ezzat, S. (2009) 'Histone-acetylated control of fibroblast growth factor receptor 
2 intron 2 polymorphisms and isoform splicing in breast cancer', Mol Endocrinol, 23(9), pp. 1397-
405. 
Zuo, P. and Manley, J.L. (1993) 'Functional domains of the human splicing factor ASF/SF2', EMBO J, 
12(12), pp. 4727-37. 
 
29 
 
Table Legend 
 
Table1. Splice sites and spliceosome members 
 
Table shows consensus splice sites within pre-mRNA sequences, together with members of the 
spliceosome that specifically bind to the splices to trigger the splicing process. Nucleotide sequences 
and location of each splice site is also indicated. 
 
Figure  Legend 
 
Figure 1. Regulation of splicing 
Pre-mRNA contains four conserved sequences required for the splicing process; snRNP U1 binds the 
5`ss therefore defining the end of the Exon 1; the small subunit of the dimeric protein U2AF 
(U2AF35) binds the 3`ss therefore defining the end of the intron and the beginning of Exon 2. Both 
U2AF35 and the larger subunit U2AF65, when bound to the polypyrimidine tract (defined by uridine 
repetition), supports the recruitment of snRNPU2 to the Branch Point (marked by an adenine). The 
figure highlights that the binding of U2AF to both the 3` splice site and the polypyrimidine tract is 
inhibited by a nearby Exonic Splicing Silencer (ESS) and an Intronic Splicing Silencer (ISS). This 
prevents the recruitment of snRNP U2 to the Branch point. Exon/intron splicing enhancers (ESEs, 
ISEs) and exon/intron splicing silencers (ESSs, ISSs) are defined recondition RNA for splicing factors 
which, in turn, either promote or prevent the splicing process. Splicing factors either guide or block 
the interactions between the spliceosome and splice sites. Different splicing factors can also compete 
with each other for binding the same motif, to influence the selection of the nearby splice sites. 
 
Figure 2.  Alternative splicing network of RNA-binding proteins and their target cancer-related 
genes 
The network shows alternative splicing events that occur in a selection of cancer-related genes due to 
the activity of specific splicing factors:  SRs (red circle), hnRNPs (green circle) and RNA-binding 
proteins (purple circle). Splice variants either produced (arrows) or prevented (bar) by SRs, hnRNPs 
and other RNA-binding proteins are indicated respectively.   
 
Figure 3.  Splice variants and biological effects driven by overexpression/downregulation of 
SRSF1  
The figure shows specific splicing events and the resulting biological effects driven by deregulation of 
SRSF1. Splice variants and resulting biological effects either promoted (arrow) or prevented (bar) by 
overexpression of SRSF1 are reported (upper panel) whilst splice variants promoted by 
downregulation of SRSF1 are indicated underneath. 
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Figure 4. Splice variants and biological effects driven by overexpression of hnRNP A1  
The figure shows specific splicing events and the resulting biological effects driven by overexpression 
of hnRNP A1. Splice variants and resulting biological effects either promoted (arrow) or prevented 
(bar) by overexpression of hnRNP A1 are reported (upper panel). 
 
 
 
 
 
 
 
 





